samedan logo
 
 
 
spacer
home > pmps > summer 2020 > adopting connected drug delivery devices
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Adopting Connected Drug Delivery Devices

Against the backdrop of an ageing population and a rise in non-communicable diseases, digitally transforming the healthcare system is essential. Even before the current world health crisis, healthcare systems were feeling the strain due to increasing demand, which was placing more pressure on resources. If patient self-management and teleconsultations are not systematically developed and expanded, hard-pressed health services around the world will struggle to withstand the pressure.

The current health crisis shines a light on the value of both enabling remote consultations with clinicians and the ability for patients to self-administer medication in the home. In fact, one recent study has highlighted remote services as one of the three top benefits of digitalisation, according to healthcare stakeholders (1). However, digitally enabled remote healthcare must deliver several key capabilities to provide maximum value to patients. Digital tools must enable patient access to clinicians, and ensure prescribed therapies are administered in the right dosage and frequency. They must also monitor patient conditions and reactions.

While patient monitoring is already a well-developed area of healthcare digitalisation for chronic respiratory conditions and diabetes, for instance, strides are now being made more widely in the area of digitally connected drug delivery devices. Our own analysis estimates the global market for connected drug delivery devices (both for injection and inhalation) to be $706 million by 2025, rising from $225 million in 2020 – which represents a compound annual growth rate of over 25% (2-4). Development in this area, however, will depend on a number of key stakeholders – payers, clinicians, patients, and pharmaceutical companies – who all have influence over the adoption of connected drug delivery devices.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
George I’ons is currently Head of Product Strategy and Insights at Owen Mumford, having worked for the former original equipment manufacturer and now Pharmaceutical Services division of the organisation since 2006. His current focus is on deciphering the rapidly changing pharma and biotech sectors in relation to their needs for combination products. In his previous roles in business development he worked closely alongside R&D to develop devices for a variety of global pharmaceutical and diagnostic clients. Prior to Owen Mumford, George worked for Abbott in EMEA marketing roles in Germany, focusing on their diabetes business.
spacer
George I’ons
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement